Glyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes. Glyscend’s polymer technology platform evolved from research at Johns Hopkins University, where scientists, in collaboration with clinicians at the Royal Adelaide Hospital were evaluating the mechanisms that result in significantly improved glucose and metabolic regulation following certain types of bariatric surgery. They discovered that specifically designed polymers, delivered orally, could mimic this post-surgical effect, creating a new class of therapies for Type 2 Diabetes and potentially other metabolic disorders.
www.glyscend.com
Employees: 11-50
Total raised: $20.5M
Founded date: 2014
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.06.2020 | Series A | $20.5M | - |
Mentions in press and media 10
| Date | Title | Description | Source |
| 02.06.2023 | Glyscend Therapeutics Announces Positive Topline Phase 2a Cl... | BOSTON–(BUSINESS WIRE)–Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a ne... | brandoncap... |
| 21.09.2022 | Glyscend Therapeutics Releases New Phase 1 Biomarker Results... | GLY-200 is a First-in-Class, Oral, Gut-Targeted Approach for Treatment of Type 2 Diabetes and Relate... | en.prnasia... |
| 21.09.2022 | Glyscend Therapeutics Releases New Phase 1 Biomarker Results... | Glyscend Therapeutics, a clinical-stage biotechnology company, today reported additional biomarker r... | brandoncap... |
| 03.08.2021 | Glyscend Therapeutics commences South Australia Phase I clin... | Positive preclinical data suggests that Glyscend’s unique pill, mimicking gastric bypass surgery, wi... | brandoncap... |
| 18.06.2020 | Glyscend Therapeutics raises $20.5M Series A to advance a ne... | Baltimore-based biopharmaceutical company Glyscend Therapeutics closed a $20.5 million financing rou... | technical.... |
| 12.06.2020 | $29M investment to develop new treatment for type 2 diabetes | An orally administered treatment for type 2 diabetes (T2D), which mirrors the astonishing effect of ... | brandoncap... |
| 12.06.2020 | Glyscend Therapeutics Completes $20.5 M Series A | Glyscend Therapeutics, a privately held biopharmaceutical company developing novel treatments for ty... | citybizlis... |
| 11.06.2020 | Glyscend Therapeutics Closes $20.5M Series A Financing Round | Glyscend Therapeutics, a Baltimore, MD-based biopharmaceutical company developing novel treatments f... | finsmes.co... |
| 26.05.2017 | Here’s who won TEDCO’s 2017 ICE awards | TEDCO’s ICE awards returned to Columbus Center in Inner Harbor on Thursday night. The Maryland agen... | technical.... |
| 28.09.2016 | 31 startups that Baltimore research institutions should be v... | Universities are the secret weapon of national startup hubs like Silicon Valley and Boston. And over... | technical.... |